［1］Singh AP, Senapati S, Ponnusamy M P. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer［J］. Lancet Oncol, 2008, 9(11): 1076-1085.
［2］Auersperg N, Maines-Bandiera SL, Dyck HG. Ovarian carcinogen-esis and the biology of ovarian surface epithelium［J］. J Cell Physi-ol, 1997, 173(2): 261-265.
［3］Farley J, Ozbun LL,  Birrer MJ. Genomic analysis of epithelial ovarian cancer［J］. Cell Res, 2008, 18(5): 538-548.
［4］Hishiya A, Takayama S. Molecular chaperones as regulators of cell death［J］. Oncogene, 2008, 27(50): 6489-6506.
［5］Kaul SC,  Deocaris CC,  Wadhwa R. Three faces of mortalin: a housekeeper, guardian and killer［J］. Exp Gerontol, 2007, 42(4):  263-274.
［6］Wadhwa R, Kaul SC, Ikawa Y. Identification of a novel member of mouse hsp70 family. Its association with cellular mortal phenotype［J］. J Biol Chem, 1993, 268(9): 6615-6621.
［7］Yang L, Zhao MX, Liu W, et al. Effect of Grp75 on the alteration of apoptosis related gene Bax and NF-KB induced by glucose deprivation［J］. Acta Anatomic Sinica, 2009,40（4）:594-598.(in Chinese)
杨玲, 赵明霞, 刘雯, 等. 葡萄糖调节蛋白75对缺糖诱导的凋亡相关基因Bax和NF-KB改变的影响［J］. 解剖学报,2009,40（4）:594-598.
［8］Pizzatti L, Sa LA, de Souza JM. Altered protein profile in chronic myeloid leukemia chronic phase identified by a comparative proteomic study［J］. Biochim Biophys Acta, 2006, 1764(5): 929-942.
［9］Rozenberg P, Kocsis J, Saar M. Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer［J］. Int J Cancer, 2013, 133(2): 514-518.
［10］Takano S, Wadhwa R, Yoshii Y. Elevated levels of mortalin expression in human brain tumors［J］.Exp Cell Res, 1997, 237(1): 38-45.
［11］Wadhwa R, Takano S, Kaur K. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis［J］. Int J Cancer, 2006, 118(12): p. 2973-2980.
［12］Yi X, Luk JM, Lee NP. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence［J］. Mol Cell Proteomics, 2008, 7(2): 315-325.
［13］Yang L, Li H, Jiang Y. Inhibition of mortalin expression reverses cisplatin resistance and attenuates growth of ovarian cancer cells［J］. Cancer Lett, 2013, 336(1): 213-221.
［14］Zhou BB,  Elledge SJ, The DNA damage response: putting checkpoints in perspective［J］. Nature, 2000, 408(6811):  433-439.
［15］Beere HM, Wolf BB, Cain K. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome［J］. Nat Cell Biol, 2000, 2(8): 469-475.
［16］Yang L, Guo W, Zhang Q. Crosstalk between Raf/MEK/ERK and PI3K/Akt in suppression of Bax conformational change by Grp75 under glucose deprivation conditions［J］. J Mol Biol, 2011, 414(5): 654-666.
［17］Boulton TG, Nye SH, Robbins D J. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF［J］. Cell, 1991, 65(4): 663-675.
［18］Kyosseva SV. Mitogen-activated protein kinase signaling［J］. Int Rev Neurobiol, 2004, 59: 201-220.
［19］Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions［J］. Biochim Biophys Acta, 2007, 1773(8):  1213-1226.
［20］Marshall CJ. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase［J］. Curr Opin Genet Dev, 1994, 4(1): 82-89.
［21］Steelman LS, Pohnert SC. Shelton JG. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis［J］. Leukemia, 2004, 18(2): 189-218.